(OTCBB:- RGRX) In the first study evaluating Thymosin ßeta 4 (Tß4) in diabetic animals it was reported that Tß4 significantly accelerates the healing of wounds in this model. These News Studies were conducted at the National Institutes of Health, in collaboration with scientists at The George Washington University Medical Center, and extend earlier published studies indicating Tß4 improved wound healing in aged, steroid-suppressed, and normal laboratory animals.

Dr. Allan Goldstein, Professor and Chairman of the Department of Biochemistry and Molecular Biology at The George Washington University Medical School and Health Sciences, Washington, D.C. and the Chief Scientific Advisor of RegeneRx, presented this most current data at the 6th Annual International Symposium on Aging Skin in Chicago, Illinois.

"In addition to confirming the other studies previously conducted at the NIH, this one continues to expand the array of possible indications for Tß4 in wound healing," according to Dr. Goldstein. "Often chronic wounds are coincident with an impaired immune system, either due to age, disease or genetics. Wound healing defects are particularly unresponsive in diabetic patients and are difficult to treat with current therapies. Tß4 represents a totally new approach to wound healing and we are looking forward to translating this research into clinical applications."

Tß4 is a naturally occurring 43-amino acid peptide that regulates actin and down-regulates certain inflammatory cytokines, both of which are vital for the healing of acute and chronic wounds. Tß4 represents a new class of wound healing compound, having been the subject of a significant amount of research at the NIH and other academic institutions. It has been shown to effectively repair dermal and corneal wounds in several animal models under a variety of conditions including those that are steroid-suppressed, aged, diabetic, as well as normal. Further, it has been delivered both topically and systemically with both routes of administration showing similar activity for dermal wounds. The fact that Tß4 seems to be active across a broad spectrum of wounds with various underlying causes apparently indicates that it is a necessary component of the wound repair process. This would not be unexpected given its mechanism of action.

RegeneRx Biopharmaceuticals, Inc., Bethesda, MD, is developing Tß4 for the treatment of acute and chronic wounds and for the treatment of a variety of human diseases involving tissue and organ repair. The company holds an exclusive worldwide license from the National Institutes of Health related to the technology, holds several patents related to the technology and has numerous patent applications pending. RegeneRx recently completed a $1.7 million round of financing that will provide funding for the initiation of human clinical trials.

The information in this press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development and commercialization of Tß4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2002 Press Release Archives